Trending...
- California: Governor Newsom signs new law to protect workers, require disclosures on AI-generated advertising - 152
- California: Governor Newsom signs legislation 9.14.2026 - 137
- California: Governor Newsom expands film and TV tax credits with new legislation, creates tax credit to support post-production jobs - 102
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company's common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on The Californer
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on The Californer
- California establishes Dolly Parton Day
- California: Governor Newsom signs bills as Los Angeles readies for 2028 Olympic and Paralympic Games
- Governor Gavin Newsom signs legislation to accelerate California's EV future, expand consumer choice, and strengthen energy independence
- Best Dodge Lemon Law Attorney in Los Angeles County
- Care En Route Launches Location-Aware Booking For Mobile Healthcare Practices
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom expands film and TV tax credits with new legislation, creates tax credit to support post-production jobs
- KayeDinero Writes Python. Does That Make Her an AI Artist? "C'mon Nah."
- Governor Newsom signs new laws to protect California elections from Trump interference
- Governor Newsom signs bill to protect California's sovereignty and guard against unauthorized military deployments
- Vydhai Launches AI Visibility Service for Dental Practices in ChatGPT, Google AI & Perplexity
- 11th Edition of Tomorrow's Filmmakers Today fellowship at 18th Annual Hola Mexico Film Festival
- California: Governor Newsom issues legislative update 9.18.26
- California: Governor Newsom announces appointments 9.18.2026
- Rentacomputer.com Highlights On-Stage Teleprompter Rentals for Lyrics, Scripts, and Cues
- Treo expands global distribution across 17+ streaming FAST and connected TV platforms
- California: Governor Newsom announces Judicial Appointments 9.18.2026
- Mystery Enterprises Receives Federal Trademark Registration for Automated Murder Mystery Game Format
- Matt Zavala of Zavala Law, PC Selected to the 2027 Super Lawyers List
- Sawgrass Ford President Attributes Dealerships Success to Long-Term Employees
- Attn: Art Editors and Art Critics: At a Multimillion dollar Art Auction, does the Second-place Bidder breathe a Sigh of Relief or a Sigh of Regret?
- Governor Newsom proclaims California POW/MIA Recognition Day
- Cal State LA Professor Stephen Rothman's 'Effortless Perfection' earns festival recognition
- Nationwide Boiler Appoints John McDonough As Chief Operating Officer
- Senior Travel Deal Of The Week: 16-Day Morocco Adventure Drops From $4,295 To $995
- Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day